<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Topiramate for the prophylaxis of episodic migraine in adults - Linde, M - 2013 | Cochrane Library</title> <meta content="Topiramate for the prophylaxis of episodic migraine in adults - Linde, M - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010610/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Topiramate for the prophylaxis of episodic migraine in adults - Linde, M - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010610/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010610" name="dc.identifier" scheme="DOI"/> <meta content="Topiramate for the prophylaxis of episodic migraine in adults" name="citation_title"/> <meta content="Mattias Linde" name="citation_author"/> <meta content="mattias.linde@ntnu.no" name="citation_author_email"/> <meta content="Wim M Mulleners" name="citation_author"/> <meta content="Canisius Wilhelmina Ziekenhuis" name="citation_author_institution"/> <meta content="Edward P Chronicle" name="citation_author"/> <meta content="University of Hawaii at Manoa" name="citation_author_institution"/> <meta content="Douglas C McCrory" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD010610" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/06/24" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010610/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010610/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010610/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [*therapeutic use]; Fructose [*analogs &amp; derivatives, therapeutic use]; Migraine Disorders [*prevention &amp; control]; Randomized Controlled Trials as Topic; Topiramate" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010610&amp;doi=10.1002/14651858.CD010610&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="PSzzz2OT";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010610\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010610\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010610\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ko","ms","hr","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010610",title:"Topiramate for the prophylaxis of episodic migraine in adults",firstPublishedDate:"Jun 24, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010610&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010610';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010610/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010610/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010610%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010610/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010610/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010610/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010610/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010610" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010610/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010610" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010610/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010610/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5211 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010610" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-sec-0082"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-sec-0029"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-sec-0034"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-sec-0035"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-sec-0052"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-sec-0072"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010610/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/appendices#CD010610-sec-0087"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/table_n/CD010610StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/table_n/CD010610StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010610/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010610/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010610/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010610/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010610/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Topiramate for the prophylaxis of episodic migraine in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010610/information#CD010610-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Mattias Linde</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010610/information#CD010610-cr-0003">Wim M Mulleners</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010610/information#CD010610-cr-0004">Edward P Chronicle</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010610/information#CD010610-cr-0005">Douglas C McCrory</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010610/information/en#CD010610-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 24 June 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010610/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010610">https://doi.org/10.1002/14651858.CD010610</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010610-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010610-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010610-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010610-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010610-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010610-abs-0002">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010610-abs-0001" lang="en"> <section id="CD010610-sec-0001"> <h3 class="title" id="CD010610-sec-0001">Background</h3> <p>Some antiepileptic drugs but not others are useful in clinical practice for the prophylaxis of migraine. This might be explained by the variety of actions of these drugs in the central nervous system. The present review is part of an update of a Cochrane review first published in 2004, and previously updated (conclusions not changed) in 2007. </p> </section> <section id="CD010610-sec-0002"> <h3 class="title" id="CD010610-sec-0002">Objectives</h3> <p>To describe and assess the evidence from controlled trials on the efficacy and tolerability of topiramate for preventing migraine attacks in adult patients with episodic migraine. </p> </section> <section id="CD010610-sec-0003"> <h3 class="title" id="CD010610-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL; <i>The Cochrane Library</i> 2012, Issue 12), PubMed/MEDLINE (1966 to 15 January 2013), MEDLINE In‐Process (current week, 15 January 2013), and EMBASE (1974 to 15 January 2013) and handsearched <i>Headache</i> and <i>Cephalalgia</i> through January 2013. </p> </section> <section id="CD010610-sec-0004"> <h3 class="title" id="CD010610-sec-0004">Selection criteria</h3> <p>Studies were required to be prospective, controlled trials of topiramate taken regularly to prevent the occurrence of migraine attacks, to improve migraine‐related quality of life, or both. </p> </section> <section id="CD010610-sec-0005"> <h3 class="title" id="CD010610-sec-0005">Data collection and analysis</h3> <p>Two review authors independently selected studies and extracted data. For headache frequency data, we calculated mean differences (MDs) between topiramate and comparator (placebo, active control, or topiramate in a different dose) for individual studies and pooled these across studies. For dichotomous data on responders (patients with ≥ 50% reduction in headache frequency), we calculated odds ratios (ORs) and, in select cases, risk ratios (RRs); we also calculated numbers needed to treat (NNTs). We calculated MDs for selected quality of life instruments. Finally, we summarised data on adverse events from placebo‐controlled trials and calculated risk differences (RDs) and numbers needed to harm (NNHs). </p> </section> <section id="CD010610-sec-0006"> <h3 class="title" id="CD010610-sec-0006">Main results</h3> <p>Twenty papers describing 17 unique trials met the inclusion criteria. Analysis of data from nine trials (1737 participants) showed that topiramate reduced headache frequency by about 1.2 attacks per 28 days as compared to placebo (MD ‐1.20; 95% confidence interval (CI) ‐1.59 to ‐0.80). Data from nine trials (1190 participants) show that topiramate approximately doubled the proportion of responders relative to placebo (RR 2.02; 95% CI 1.57 to 2.60; NNT 4; 95% CI 3 to 6). Separate analysis of different topiramate doses produced similar MDs versus placebo at 50 mg (‐0.95; 95% CI ‐1.95 to 0.04; three studies; 520 participants), 100 mg (‐1.15; 95% CI ‐1.58 to ‐0.71; six studies; 1620 participants), and 200 mg (‐0.94; 95% CI ‐1.53 to ‐0.36; five studies; 804 participants). All three doses significantly increased the proportion of responders relative to placebo; ORs were as follows: for 50 mg, 2.35 (95% CI 1.60 to 3.44; three studies; 519 participants); for 100 mg, 3.49 (95% CI 2.23 to 5.45; five studies; 852 participants); and for 200 mg, 2.49 (95% CI 1.61 to 3.87; six studies; 1025 participants). All three doses also significantly improved three or more domains of quality of life as compared to placebo. Meta‐analysis of the three studies that included more than one dose of topiramate suggests that 200 mg is no more effective than 100 mg. With regard to mean headache frequency and/or responder rate, seven trials using active comparators found (a) no significant difference between topiramate and amitriptyline (one study, 330 participants); (b) no significant difference between topiramate and flunarizine (one study, 83 participants); (c) no significant difference between topiramate and propranolol (two studies, 342 participants); (d) no significant difference between topiramate and relaxation (one study, 61 participants); but (e) a slight significant advantage of topiramate over valproate (two studies, 120 participants). Relaxation improved migraine‐specific quality of life significantly more than topiramate. In trials of topiramate against placebo, seven adverse events (AEs) were reported by at least three studies. These were usually mild and of a non‐serious nature. Except for taste disturbance and weight loss, there were no significant differences in the frequency of AEs in general, or of the seven specific AEs, between placebo and topiramate 50 mg. AEs in general and all of the specific AEs except nausea were significantly more common on topiramate 100 mg than on placebo, with NNHs varying from 3 to 25, and the RDs versus placebo were even higher for topiramate 200 mg, with NNHs varying from 2 to 17. </p> </section> <section id="CD010610-sec-0007"> <h3 class="title" id="CD010610-sec-0007">Authors' conclusions</h3> <p>Meta‐analysis demonstrates that topiramate in a 100 mg/day dosage is effective in reducing headache frequency and reasonably well‐tolerated in adult patients with episodic migraine. This provides good evidence to support its use in routine clinical management. More studies designed specifically to compare the efficacy or safety of topiramate versus other interventions with proven efficacy in the prophylaxis of migraine are needed. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010610-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010610-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010610-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010610-abs-0012">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010610-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD010610-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD010610-abs-0005">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010610-abs-0006">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010610-abs-0004" lang="en"> <h3>Topiramate for preventing migraine attacks in adults</h3> <p>Various medicines, collectively termed 'antiepileptics', are used to treat epilepsy. For several years, some of these drugs have also been used for preventing migraine attacks. For the present review, researchers in The Cochrane Collaboration reviewed the evidence about the effects of topiramate in adult patients (≥ 16 years of age) with 'episodic' migraine (headache on &lt; 15 days per month). They examined research published up to 15 January 2013 and found 17 relevant studies. Compared with placebo, topiramate reduced the frequency of migraine headaches by approximately 1.2 per month (nine studies, 1737 participants). Patients were also about twice as likely to reduce the number of their migraine headaches by 50% or more with topiramate than with placebo (nine studies, 1190 participants). Side effects associated with topiramate were common but generally mild; topiramate can, however, cause birth defects and so should be used with caution in women of childbearing age. Further research is needed comparing topiramate with other active drugs used for preventing migraine attacks. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010610-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010610-sec-0082"></div> <h3 class="title" id="CD010610-sec-0083">Implications for practice</h3> <section id="CD010610-sec-0083"> <p>Bearing in mind the limitations invoked by the methodological and reporting issues mentioned above, this review nevertheless helps to provide a rational framework for the application of topiramate for the preventive management of migraine headache in clinical practice. Topiramate has been investigated in 17 independent clinical trials (10 of which included placebo as a comparator), with generally consistent results. It can be concluded from this review that topiramate is of proven efficacy in migraine prevention and is suitable for routine clinical use. It must be stressed, however, that this review does not provide definite evidence for the efficacy of topiramate in the management of other aspects of the condition (eg, prodromal symptoms, aura symptoms). Likewise, the conclusions in this review cannot be extrapolated to chronic migraine, transformed migraine, or chronic daily headache. None of these conditions was considered for this review, as properly validated definitions are as yet lacking. </p> <p>The seven trials allowing comparisons with another active intervention suggest that topiramate is marginally more effective than valproate, but no more effective than amitriptyline, flunarizine, propranolol, or relaxation, although these results must be viewed with caution for methodological reasons. It must be stressed that on a case‐to‐case basis, rational prescriber preferences may be justified due to differences in side effect profiles. Data from pregnancy registries indicate that infants exposed to topiramate have a higher incidence of major congenital malformations (<a href="./references#CD010610-bbs2-0055" title="Janssen‐Cilag . Topimax product information. LIF—the research based pharmaceutical industry; 2013. www.fass.se (accessed 15 March 2013). ">Janssen‐Cilag 2013</a>). For migraine, topiramate should therefore not be used during pregnancy or in women of childbearing potential not using effective contraception. Moreover, because topiramate causes increased excretion of ethinyl estradiol, low‐dose hormonal contraception may be less effective in women taking topiramate, and other means of contraception may be warranted. Although adverse events were reported by a large proportion of study participants treated with topiramate, these were usually mild and of a non‐serious nature. Thus it can be concluded that topiramate is reasonably well‐tolerated. </p> </section> <h3 class="title" id="CD010610-sec-0084">Implications for research</h3> <section id="CD010610-sec-0084"> <p>There is a need for more studies designed specifically to compare the efficacy or safety of topiramate to other interventions with proven efficacy in the prophylaxis of migraine. Also needed are (a) better studies of dose versus effect; (b) studies of which patients do and do not respond, and why; (c) long‐term studies; (d) studies post‐withdrawal of topiramate after effective use for several months. </p> <p>Future trialists should also be encouraged to follow the recommendations of the International Headache Society (<a href="./references#CD010610-bbs2-0068" title="Tfelt‐HansenP , PascualJ , RamadanN , DahlöfC , D'AmicoD , DienerHC , et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia2012;32(1):6‐38. [MEDLINE: 22384463] ">Tfelt‐Hansen 2012</a>) with regard to both trial design and reporting of data. </p> <p>Little is definitely known about the mechanism of action of topiramate in migraine prophylaxis (<a href="./references#CD010610-bbs2-0049" title="EdvinssonL , LindeM . New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet2010;376(9741):645‐55. [MEDLINE: 20416945] ">Edvinsson 2010</a>). A considerable amount of basic science research in both animal models and human neuroscience laboratories will be necessary in order to discover which of the many potential actions of this drug are causative in the reduction of headache frequency. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010610-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010610-sec-0029"></div> <section id="CD010610-sec-0030"> <h3 class="title" id="CD010610-sec-0030">Description of the condition</h3> <p>Migraine is a common and disabling health problem among children and predominantly young and middle‐aged adults. Surveys from the main regions of the world suggest that the global prevalence of migraine is 14.7% (18.8% among women and 10.7% among men) (<a href="./references#CD010610-bbs2-0051" title="VosT , FlaxmanAD , NaghaviM , LozanoR , MichaudC , EzzatiM , et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990‐2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet2013;380(9859):2163‐96. [MEDLINE: 23245607] ">GBD 2010 Study</a>). This disorder results in significant disability and work loss, and several studies have addressed the issue of the costs of migraine. In one of the most recent publications, aggregate direct and indirect costs to society due to migraine among adults in the European Union were estimated to amount to 50 billion Euros (67 billion US dollars) annually, or about 1222 Euros (1634 US dollars) annually per sufferer (<a href="./references#CD010610-bbs2-0057" title="LindeM , GustavssonA , StovnerLJ , SteinerTJ , BarréJ , KatsaravaZ , et al. The cost of headache disorders in Europe: the Eurolight project. European Journal of Neurology2012;19(5):703‐11. [MEDLINE: 22136117] ">Linde 2012</a>). </p> </section> <section id="CD010610-sec-0031"> <h3 class="title" id="CD010610-sec-0031">Description of the intervention</h3> <p>Drug therapy for migraine falls into two categories: acute and preventive. Acute therapy aims at the symptomatic treatment of the head pain and other symptoms associated with an acute attack of migraine. The primary goals of preventive treatment are to reduce attack frequency, severity, and duration. Moreover, such therapy is commonly employed in an attempt to improve responsiveness to acute treatment, enhance functional status, and reduce disability. Evidence‐based guidelines on the drug treatment of migraine have been developed and published by the European Federation of Neurological Societies (EFNS; <a href="./references#CD010610-bbs2-0050" title="EversS , AfraJ , FreseA , GoadsbyPJ , LindeM , MayA , et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. European Journal of Neurology2009;16(9):968‐81. [MEDLINE: 19708964] ">Evers 2009</a>). These guidelines suggest that prophylactic therapy should be considered for patients with migraine when quality of life, business duties, or school attendance are severely impaired; when the frequency of attacks is two or more per month; when there is a lack of response to acute drug treatment; and when frequent, very long, or uncomfortable auras occur. </p> <p>This review considers the evidence for the efficacy and tolerability of topiramate for preventing episodic migraine in adults. The prophylactic treatment of migraine in children is the subject of a separate Cochrane review (<a href="./references#CD010610-bbs2-0069" title="VictorS , RyanS . Drugs for preventing migraine headaches in children. Cochrane Database of Systematic Reviews2003, Issue 4. [DOI: 10.1002/14651858.CD002761] ">Victor 2003</a>). </p> <p>Topiramate is a sulphamate‐substituted monosaccharide (2,3:4,5‐Bis‐O‐(1‐methylethylidene)‐b‐D‐fructo‐pyranose sulfamate) derived from the naturally occurring sugar D‐fructose (<a href="./references#CD010610-bbs2-0049" title="EdvinssonL , LindeM . New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet2010;376(9741):645‐55. [MEDLINE: 20416945] ">Edvinsson 2010</a>). The absolute bioavailability, or oral bioavailability, of topiramate is 81% to 95% and is not affected by food. The distribution volume for women is approximately 50% that of men. Topiramate is metabolised to a moderate degree (circa 20%). Six metabolites have been identified. Total clearance is low (20 to 30 mL/min) after oral intake. This occurs predominantly via renal excretion (renal clearance 10 to 20 mL/min). Topiramate has a long half‐life (19 to 25 hours). Patients with normal renal function may need four to eight days to reach steady‐state plasma concentrations. The typical dose range of topiramate used in migraine is 50 to 200 mg. </p> </section> <section id="CD010610-sec-0032"> <h3 class="title" id="CD010610-sec-0032">How the intervention might work</h3> <p>We use the term 'antiepileptics' here to refer generally to those drugs in common use for the treatment of epilepsy. The pharmacological treatment of epilepsy can be traced back as far as 1857, but the period of greatest development of antiepileptics was between 1935 and 1960, when 13 drugs were developed and marketed (<a href="./references#CD010610-bbs2-0065" title="PorterRJ , MeldrumBS . Antiepileptic drugs. In: KatzungBG editor(s). Basic and Clinical Pharmacology. 5th Edition. Norwalk, CT: Appleton &amp; Lange, 1992:331‐49. ">Porter 1992</a>). In recent decades, renewed interest has led to the development of several novel antiepileptics which may confer advantages in tolerability (<a href="./references#CD010610-bbs2-0047" title="DalkaraS , KarakurtA . Recent progress in anticonvulsant drug research: strategies for anticonvulsant drug development and applications of antiepileptic drugs for non‐epileptic central nervous system disorders. Current Topics in Medicinal Chemistry2012;12(9):1033‐71. [MEDLINE: 22352861] ">Dalkara 2012</a>), and these are beginning to be used in migraine also. </p> <p>The use of antiepileptics for the prophylactic treatment of migraine is theoretically warranted by several known modes of action which relate either to the general modulation of pain systems or more specifically to systems involved in the pathophysiology of migraine (<a href="./references#CD010610-bbs2-0066" title="SilbersteinS , SaperJ , BerensonF , SomogyiM , McCagueK , D'SouzaJ . Oxcarbazepine in migraine headache: a double‐blind, randomized, placebo‐controlled study. Neurology2008;70(7):548‐55. [MEDLINE: 18268247] ">Silberstein 2008</a>; <a href="./references#CD010610-bbs2-0070" title="WiffenPJ , CollinsS , McQuayHJ , CarrollD , JadadA , MooreRA . Anticonvulsant drugs for acute and chronic pain. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD001133.pub3] ">Wiffen 2010</a>). It is necessary to point out, however, that it is not currently possible to state with any certainty which particular mode or modes of action of topiramate are relevant to the prophylaxis of migraine (<a href="./references#CD010610-bbs2-0049" title="EdvinssonL , LindeM . New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. Lancet2010;376(9741):645‐55. [MEDLINE: 20416945] ">Edvinsson 2010</a>). The efficacy of topiramate in migraine seems to be mediated by the interaction with multiple sites of action. It decreases the frequency of action potentials elicited by depolarising electric current, which gives expression to a blockade of voltage‐dependent Na<sup>+</sup> channels. Topiramate modulates cortical excitability in migraineurs, but it does not appear that this alone explains the efficacy in migraine prophylaxis. Topiramate inhibits the excitatory activity of glutamate at the receptor subtype for kainate/AMPA. It has been shown to inhibit neurons of the trigeminocervical complex via a GABA‐mediated mechanism. Furthermore, topiramate inhibits the release of CGRP from prejunctional trigeminal neurons. An inhibitory effect on high‐voltage‐dependent (HVA) Ca<sup>2+</sup> channels especially in periaqueductal grey is a possible mechanism to explain the therapeutic effect in migraine. A differential sensitivity to topiramate has been observed for HVA Ca<sup>2+</sup> channels located on cortical neurons and those in the periaqueductal grey region (PAG). Topiramate inhibits N‐, P‐, and L‐type channels in PAG neurons, whereas in cortical neurons it modulates only P‐ and L‐type channels. Chronic, but not acute, treatment suppresses cortical spreading depression in rats. Long‐term effects on gene regulation have to be considered. Collectively this points towards a reduction in excitatory transmission and increase in inhibitory neurotransmission. </p> </section> <section id="CD010610-sec-0033"> <h3 class="title" id="CD010610-sec-0033">Why it is important to do this review</h3> <p>Some antiepileptic drugs are marketed specifically for migraine prophylaxis. The EFNS (<a href="./references#CD010610-bbs2-0050" title="EversS , AfraJ , FreseA , GoadsbyPJ , LindeM , MayA , et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. European Journal of Neurology2009;16(9):968‐81. [MEDLINE: 19708964] ">Evers 2009</a>) and the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (<a href="./references#CD010610-bbs2-0067" title="SilbersteinSD , HollandS , FreitagF , DodickDW , ArgoffC , AshmanE , Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence‐based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology2012;78(17):1337‐45. [MEDLINE: 22529202] ">Silberstein 2012</a>) list topiramate among first‐line migraine prophylactics. There is a fairly substantial body of evidence from controlled trials supporting the efficacy of many of the agents used for preventing migraine, yet such therapies are used by only a small percentage of patients with migraine — 3% to 12% in various studies (<a href="./references#CD010610-bbs2-0046" title="ClarkeCE , MacMillanL , SondhiS , WellsNE . Economic and social impact of migraine. QJM1996;89(1):77‐84. [MEDLINE: 8730346] ">Clarke 1996</a>; <a href="./references#CD010610-bbs2-0048" title="EdmeadsJ , FindlayH , TugwellP , Pryse‐PhillipsW , NelsonRF , MurrayTJ . Impact of migraine and tension‐type headache on life‐style, consulting behaviour, and medication use: a Canadian population survey. Canadian Journal of Neurological Sciences1993;20(2):131‐7. [MEDLINE: 8334575] ">Edmeads 1993</a>; <a href="./references#CD010610-bbs2-0063" title="MehuysE , PaemeleireK , VanHeesT , ChristiaensT , VanBortelLM , VanTongelenI , et al. Self‐medication of regular headache: a community pharmacy‐based survey. European Journal of Neurology2012;19(8):1093‐9. [MEDLINE: 22360745] ">Mehuys 2012</a>). It is hoped that this review and others like it will increase awareness of migraine prophylactic treatment options and help to provide a systematic basis for making the best possible choice of such therapy in those individuals in need of it. </p> <p>The present review is part of a series of reviews which, taken together, represent an update of a Cochrane review on 'Anticonvulsant drugs for migraine prophylaxis' (<a href="./references#CD010610-bbs2-0071" title="ChronicleEP , MullenersWM . Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2] ">Chronicle 2004</a>; <a href="./references#CD010610-bbs2-0072" title="MullenersWM , ChronicleEP . Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia2008;28(6):585‐97. [MEDLINE: 18454787] ">Mulleners 2008</a>; first published in 2004, and previously updated (conclusions not changed) in 2007). The old review has been split into four separate reviews for updating: </p> <p> <ol id="CD010610-list-0001"> <li> <p>Topiramate for the prophylaxis of episodic migraine in adults (the present review; <a href="./references#CD010610-bbs2-0058" title="LindeM , MullenersWM , ChronicleEP , McCroryDC . Topiramate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010610] ">Linde 2013a</a>) </p> </li> <li> <p>Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults (<a href="./references#CD010610-bbs2-0059" title="LindeM , MullenersWM , ChronicleEP , McCroryDC . Valproate (valproic acid or sodium valproate or a combination of the two) for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010611] ">Linde 2013b</a>) </p> </li> <li> <p>Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults (<a href="./references#CD010610-bbs2-0060" title="LindeM , MullenersWM , ChronicleEP , McCroryDC . Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010609] ">Linde 2013c</a>) </p> </li> <li> <p>Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults (<a href="./references#CD010610-bbs2-0061" title="LindeM , MullenersWM , ChronicleEP , McCroryDC . Antiepileptics other than gabapentin, pregabalin, topiramate, and valproate for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD010608] ">Linde 2013d</a>) </p> </li> </ol> </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010610-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010610-sec-0034"></div> <p>To describe and assess the evidence from controlled trials on the efficacy and tolerability of topiramate for preventing migraine attacks in adult patients with episodic migraine. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010610-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010610-sec-0035"></div> <section id="CD010610-sec-0036"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010610-sec-0037"> <h4 class="title">Types of studies</h4> <p>The International Headache Society (IHS) has provided a useful document setting out guidelines for the conduct of clinical trials in migraine, to which current investigators are encouraged to adhere (<a href="./references#CD010610-bbs2-0068" title="Tfelt‐HansenP , PascualJ , RamadanN , DahlöfC , D'AmicoD , DienerHC , et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia2012;32(1):6‐38. [MEDLINE: 22384463] ">Tfelt‐Hansen 2012</a>). This document was not used as the sole basis for considering studies in this review, as too many potentially informative past studies would likely have been excluded on methodological grounds. However, many of its recommendations have been used as a basis for what follows. </p> <p>Included studies were required to be prospective, controlled trials of self administered topiramate taken regularly to prevent the occurrence of migraine attacks, to improve migraine‐related quality of life, or both. We included trials only if allocation to treatment groups was randomised or pseudo‐randomised (based on some non‐random process unrelated to the treatment selection or expected response). Blinding was not required. We excluded concurrent cohort comparisons and other non‐experimental designs. </p> </section> <section id="CD010610-sec-0038"> <h4 class="title">Types of participants</h4> <p>Study participants were required to be adults (at least 16 years of age) and to meet reasonable criteria designed to distinguish migraine from tension‐type headache. If patients with both types of headache were included in a trial, results were required to be stratified by headache diagnosis. We did not require the use of a specific set of diagnostic criteria (eg, <a href="./references#CD010610-bbs2-0044" title="Ad Hoc Committee on the Classification of Headache of the National Institute of Neurological Diseases and Blindness. Classification of headache. JAMA1962;179(9):717‐8. ">Ad Hoc Cttee 1962</a>; <a href="./references#CD010610-bbs2-0053" title="Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia1988;8 Suppl 7:1‐96. ">IHS Cttee 1988</a>; <a href="./references#CD010610-bbs2-0052" title="Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia2004;24 Suppl 1:1‐160. ">ICHD‐II 2004</a>), but migraine diagnoses had to be based on at least some of the distinctive features of migraine, eg, nausea/vomiting, severe head pain, throbbing character, unilateral location, phono/photophobia, or aura. Secondary headache disorders had to be excluded using reasonable criteria. </p> <p>We anticipated that some of the trials identified would include patients described as having mixed migraine and tension‐type headaches or combination headaches, and the protocol for this review described detailed procedures for dealing with such trials. In the end, no such precautions were necessary. We excluded studies evaluating treatments for chronic daily headache, chronic migraine, and transformed migraine. The reasons for this are: (a) the definition of chronic migraine is still heavily debated, and a revision of the 2004 IHS criteria for this condition has been proposed (<a href="./references#CD010610-bbs2-0064" title="OlesenJ , BousserM‐G , DienerH‐C , DodickD , FirstM , GoadsbyPJ , et al. Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia2006;26(6):742‐6. [MEDLINE: 16686915] ">Olesen 2006</a>); (b) transformed migraine and chronic daily headache, although commonly used terms, are insufficiently validated diagnoses; (c) the separation of these conditions from headache due to medication overuse is not always clear in many studies; and (d) there is some evidence that suggests that chronic migraine may be more refractory to standard prophylactic treatment than episodic migraine. We explicitly excluded trials and treatment groups including only patients with tension‐type headache. </p> </section> <section id="CD010610-sec-0039"> <h4 class="title">Types of interventions</h4> <p>Included studies were required to have at least one arm in which topiramate (without concomitant use of other migraine prophylactic treatment) was given regularly during headache‐free intervals with the aim of preventing the occurrence of migraine attacks, improving migraine‐related quality of life, or both. Acceptable comparator groups included placebo, no intervention, active drug treatment (ie, with proven efficacy, not experimental), the same drug treatment with a clinically relevant different dose, and non‐pharmacological therapies with proven efficacy in migraine. The analysis included only drugs and dosages that are commercially available. </p> <p>We recorded any data reported on treatment compliance in the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table. After examination of these data, it did not seem necessary to stratify the analysis by compliance. </p> <p>We anticipated that most trials would permit the use of medication for acute migraine attacks experienced during the trial period. We therefore recorded descriptions of trial rules concerning the use of acute medication in the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table whenever such information was provided. We did not otherwise model or adjust for this factor in our analysis. </p> </section> <section id="CD010610-sec-0040"> <h4 class="title">Types of outcome measures</h4> <p>We collected and analysed trial data on headache frequency, responders (patients with ≥ 50% reduction in headache frequency), quality of life, and adverse events. </p> </section> </section> <section id="CD010610-sec-0041"> <h3 class="title">Search methods for identification of studies</h3> <p>Search strategies used in our earlier review (<a href="./references#CD010610-bbs2-0071" title="ChronicleEP , MullenersWM . Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2] ">Chronicle 2004</a>; <a href="./references#CD010610-bbs2-0072" title="MullenersWM , ChronicleEP . Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia2008;28(6):585‐97. [MEDLINE: 18454787] ">Mulleners 2008</a>) are detailed in <a href="./appendices#CD010610-sec-0088">Appendix 1</a> (last search date 31 December 2005). For the present update, trained information specialists developed detailed search strategies for each database searched (<a href="./appendices#CD010610-sec-0095">Appendix 2</a>). The new searches overlapped the old searches by a full year to ensure complete coverage. The last search date for all updated searches was 15 January 2013. </p> <p>Databases searched for this update were:</p> <p> <ul id="CD010610-list-0002"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; <i>The Cochrane Library</i> 2012, Issue 12; years searched = 2005 to 2012); </p> </li> <li> <p>MEDLINE (via OVID), 2005 to 15 January 2013;</p> </li> <li> <p>MEDLINE In‐Process (via OVID), current week, 15 January 2013;</p> </li> <li> <p>EMBASE (via OVID), 2005 to 15 January 2013.</p> </li> </ul> </p> <p>Additional strategies for identifying trials included searching the reference lists of review articles and included studies, searching books related to headache, and consulting experts in the field. We attempted to identify all relevant published trials, irrespective of language. We handsearched two journals, <i>Headache</i> and <i>Cephalalgia</i>, in their entirety through January 2013. </p> </section> <section id="CD010610-sec-0042"> <h3 class="title" id="CD010610-sec-0042">Data collection and analysis</h3> <section id="CD010610-sec-0043"> <h4 class="title">Selection of studies</h4> <p>Two of us independently screened titles and abstracts of studies identified by the literature search for eligibility. Papers that could not be excluded with certainty on the basis of information contained in the title and/or abstract were retrieved in full for screening. Disagreements were resolved through discussion. We retrieved papers passing this initial screening process, and two of us independently reviewed the full texts. Disagreements at the full‐text stage were resolved through internal discussion and, in a few cases, through correspondence with members of the editorial staff of the Cochrane Pain, Palliative and Supportive Care Review Group. We were not blinded to study investigators' names and institutions, journal of publication, or study results at any stage of the review. </p> <p>The search strategy described above identified a large number of short conference and journal abstracts. The majority of these either (a) reported partial results of ongoing trials; (b) provided insufficient information on trial design or results; (c) were early reports of included studies; or (d) were reproductions of abstracts of papers published in full (for example, the journal <i>Headache</i> reproduces abstracts of interest to readers, and these are found by PubMed). We agreed that short abstracts of this kind would be excluded from consideration. </p> </section> <section id="CD010610-sec-0044"> <h4 class="title">Data extraction and management</h4> <p>Two of us independently abstracted information on patients, methods, interventions, efficacy outcomes, and adverse events from the original reports onto specially designed, pre‐tested paper forms. Disagreements were again resolved through discussion. </p> <p>We anticipated that trials would vary in length, that outcomes would be measured over various units of time (eg, number of attacks per two weeks versus number of attacks per four weeks), and that results would be reported for numerous different time points (eg, four‐week headache frequency at two months versus at four months). We attempted to standardise the unit of time over which headache frequency was measured at 28 days (four weeks) wherever possible. We recorded outcomes beginning four weeks after the start of treatment and continued through all later assessment periods. We made decisions about which time points to include in the final analysis once the data had been collected. </p> <p>We anticipated that outcomes measured on a continuous scale (eg, headache frequency) would be reported in a variety of ways, eg, as mean pre‐treatment, post‐treatment, and/or change scores. Among change scores, we preferred the mean of within‐patient changes (from baseline to on‐treatment in a parallel‐group trial) over the change in group means because the first both results in a lower variance (taking into account the correlation between baseline and post‐treatment scores in each patient) and adjusts for imbalances in baseline headache frequencies, while the latter has only the second advantage. When neither type of change score was reported, we compared post–treatment means between groups, assuming that baseline data would be balanced due to randomisation. We anticipated that many trials would report group means, without reporting data on the variance associated with these means. In such cases, we attempted to calculate or estimate variances based on primary data, test statistics, and/or error bars in graphs. </p> <p>When efficacy outcomes were reported in dichotomous form (success/failure), we required that the threshold for distinguishing between treatment success and failure be clinically significant; for example, we interpreted a ≥ 50% reduction in headache frequency as meeting this criterion. In such cases, we recorded, for each treatment arm, the number of patients included in the analysis and the number with each outcome. </p> <p>The protocol for this review specified rules for dealing with outcome data reported on an ordinal scale (eg, for reduction in headache frequency: 0%, 1% to 24%, 25% to 49%, 50% to 74%, 75% to 99%, 100%) but, in fact, none of the included trials reported ordinal data for outcomes of interest. </p> <p>We envisaged that the preferred methods of collecting and presenting data on quality of life would most likely be the Migraine‐Specific Questionnaire (MSQ) and the Medical Outcomes Study 36‐item Short‐Form Health Survey (SF‐36). However, other instruments and other types of outcomes related to quality of life (eg, work absenteeism) were not excluded a priori, and these data were kept under review before specifying rules for analysing outcome data in this domain. </p> <p>We recorded the proportion of patients reporting adverse events for each treatment arm wherever possible. The identity and rates of specific adverse events were also recorded. We anticipated that reporting of adverse events would vary greatly across trials with regard to the terminology used, method of ascertainment, and classification of adverse events as drug‐related or not and as severe or not. </p> </section> <section id="CD010610-sec-0045"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We completed a 'Risk of bias' table for each study, using assessments of random sequence generation (selection bias), allocation concealment (selection bias), blinding of participants and personnel (performance bias), blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and selective reporting (reporting bias). For new studies identified in the present update, two of us completed this assessment independently; for older studies, one of us performed the assessment and a second author reviewed and commented on it. Disagreements were resolved through discussion. </p> <p>We also assessed the methodological quality of individual trials using the scale devised by Jadad and colleagues (<a href="./references#CD010610-bbs2-0054" title="JadadAR , MooreRA , CarrollD , JenkinsonC , ReynoldsDJ , GavaghanDJ , et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled Clinical Trials1996;17(1):1‐12. [MEDLINE: 8721797] ">Jadad 1996</a>), operationalised as follows: </p> <p> <ol id="CD010610-list-0003"> <li> <p>Was the study described as randomised? (1 = yes; 0 = no)</p> </li> <li> <p>Was the method of randomisation well described and adequate? (0 = not described; 1 = described and adequate; ‐1 = described, but not adequate) </p> </li> <li> <p>Was the study described as double‐blind? (1 = yes; 0 = no)</p> </li> <li> <p>Was the method of double‐blinding well described and adequate? (0 = not described; 1 = described and adequate; ‐1 = described, but not adequate) </p> </li> <li> <p>Was there a description of withdrawals and dropouts sufficient to determine the number of patients in each treatment group entering and completing the trial? (1 = yes; 0 = no) </p> </li> </ol> </p> <p>Each trial thus received a score of 0 to 5 points, with higher scores indicating higher quality in the conduct or reporting of the trial. Two review authors scored the studies independently, and a consensus score was then arrived at through discussion. The consensus score is reported for each study in the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table and was not used as a weighting in statistical analyses. </p> </section> <section id="CD010610-sec-0046"> <h4 class="title">Measures of treatment effect</h4> <p>The primary outcome considered for the efficacy analysis was headache frequency. Among headache frequency measures, we preferred number of migraine attacks to number of days with migraine. The latter measure confusingly incorporates attack duration into the measure of headache frequency. Moreover, attack duration is affected by the use of symptomatic medication, which is permitted in most trials. We also analysed headache frequency in terms of a responder rate, or the proportion of patients with a ≥ 50% reduction in headache frequency from pre‐ to post‐treatment. </p> <p>As noted above (<a href="#CD010610-sec-0044">Data extraction and management</a>), we kept patient‐reported quality of life data under review as studies were selected. For comparisons with placebo and direct dose comparisons, the data chosen for a rigorous analysis were measured by the Migraine‐Specific Questionnaire (MSQ) and the Medical Outcomes Study 36‐item Short‐Form Health Survey (SF‐36). For active treatment comparisons, we analysed data measured by the Migraine Disability Assessment (MIDAS) and the Migraine‐Specific Quality of Life Questionnaire (MSQoL). We decided not to include data measured by the less commonly used Headache Impact Test (HIT‐6), Quality of Life Enjoyment and Satisfaction Questionnaire–Short Form (Q‐LES‐Q‐SF), and Medical Outcomes Study 12‐item Short‐Form Health Survey (SF‐12). </p> <p>The analysis considered only outcome data obtained directly from the patient and not those judged by the treating physician or study personnel. Efficacy data based on contemporaneous and timed (usually daily) recording of headache symptoms were preferred to those based on global or retrospective assessments. </p> <p>In addition, we tabulated adverse events for each included study.</p> </section> <section id="CD010610-sec-0047"> <h4 class="title">Unit of analysis issues</h4> <p>In the case of cross‐over trial designs, we anticipated that the data reported would normally not permit analysis of paired within‐patient data. We therefore analysed cross‐over trials as if they were parallel‐group trials, combining data from all treatment periods. If a carry‐over effect was found and data were reported by period, then the analysis was restricted to period‐one data only. In no trial were complete within‐patient data reported, so within‐patient improvement scores were not calculated. </p> </section> <section id="CD010610-sec-0048"> <h4 class="title">Dealing with missing data</h4> <p>Where data were missing or inadequate, we attempted to obtain these data by correspondence with study authors. </p> </section> <section id="CD010610-sec-0049"> <h4 class="title">Assessment of heterogeneity</h4> <p>We tested estimates of efficacy (both mean differences (MDs) and odds ratios (ORs)) for homogeneity. When significant heterogeneity was present, we made an attempt to explain the differences based on the clinical characteristics of the included studies. We did not statistically combine studies that were clinically dissimilar. However, when a group of studies with statistically heterogeneous results appeared to be clinically similar, we did combine study estimates. We performed all pooled analyses using a random‐effects model. </p> <p>As a sensitivity analysis, we also planned to calculate a pooled effect estimate using a fixed‐effect model for major outcomes (headache frequency, responder rate, and any adverse event) when the random‐effects result was near‐significant (0.05 ≤ P ≤ 0.15) and the pooled studies were homogeneous (heterogeneity statistics: P &gt; 0.15/I<sup>2</sup> &lt; 30%). Such a sensitivity analysis would evaluate whether conclusions might differ based on the statistical model used for pooling in situations where a fixed‐effect model might reasonably be considered instead of a random‐effects model. In fact, however, no such sensitivity analyses were warranted in the present review. </p> </section> <section id="CD010610-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We anticipated that continuous outcome measures of headache frequency would be reported on different and often incompatible scales. Although we attempted to standardise the extraction of headache frequency data to a 28‐day (four‐week) period, this was not possible in every case. In our previous review (<a href="./references#CD010610-bbs2-0071" title="ChronicleEP , MullenersWM . Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2] ">Chronicle 2004</a>; <a href="./references#CD010610-bbs2-0072" title="MullenersWM , ChronicleEP . Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia2008;28(6):585‐97. [MEDLINE: 18454787] ">Mulleners 2008</a>), we therefore analysed these data using the standardised mean difference (SMD, with 95% confidence intervals (CIs)) rather than the mean difference (MD). The introduction of change scores in the newly included studies for some of the reviews in this series necessitated a change in the analysis plan from SMDs to MDs. The latter also has the advantage of giving a result in clinically meaningful units (ie, x fewer migraines per 28 days). </p> <p>We used dichotomous data meeting our definition of a clinically significant threshold to calculate odds ratios (ORs), with 95% CIs. Although we prefer ORs because of their statistical properties, some readers may find it simpler to interpret the clinical significance of our findings using risk ratios (RRs); we have therefore calculated RRs where appropriate. We additionally computed numbers needed to treat (NNTs), with 95% CIs, as the reciprocal of the risk difference (RD) versus placebo (<a href="./references#CD010610-bbs2-0062" title="McQuayH , MooreR . An Evidence‐based Resource for Pain Relief. Oxford: Oxford University Press, 1998. ">McQuay 1998</a>). </p> <p>In the same way, we used data on the proportion of patients reporting adverse events to calculate RDs and numbers needed to harm (NNHs). </p> </section> <section id="CD010610-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We undertook subgroup analyses by dose where possible. We considered further subgroup analyses by method of randomisation and by completeness of blinding, but did not undertake them because of insufficient data. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010610-sec-0052" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010610-sec-0052"></div> <section id="CD010610-sec-0053"> <h3 class="title">Description of studies</h3> <section id="CD010610-sec-0054"> <h4 class="title">Results of the search</h4> <p>The PubMed search strategy for our previous review (<a href="./references#CD010610-bbs2-0071" title="ChronicleEP , MullenersWM . Anticonvulsant drugs for migraine prophylaxis. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD003226.pub2] ">Chronicle 2004</a>; <a href="./references#CD010610-bbs2-0072" title="MullenersWM , ChronicleEP . Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia2008;28(6):585‐97. [MEDLINE: 18454787] ">Mulleners 2008</a>) yielded 1089 potentially eligible citations, while the EMBASE and CENTRAL searches yielded 290 and 6952 citations, respectively. No additional citations were retrieved from the Cochrane Pain, Palliative &amp; Supportive Care Trials Register or from other sources. After title and abstract screening, we obtained 58 published papers on antiepileptics for full‐text scrutiny. Of these, 16 (six included, 10 excluded) investigated topiramate. </p> <p>The MEDLINE search strategy for the present update (from 2005 on) yielded 188 citations as possible candidates for the current series of reviews on antiepileptic drugs for migraine prophylaxis; the search of MEDLINE In‐Process identified an additional 20 citations. The EMBASE and CENTRAL updates identified 484 and 85 citations, respectively. Three additional study reports (all unpublished and all pertaining to gabapentin) were identified from other sources. After title and abstract screening, we obtained 37 published and three unpublished papers on antiepileptics for full‐text scrutiny. Of these, 30 (14 included, 16 excluded) investigated topiramate. </p> <p>Thus, for the present update, we reviewed a total of 46 papers on topiramate at the full‐text screening stage. Of these, we included 20 papers and excluded 26. </p> </section> <section id="CD010610-sec-0055"> <h4 class="title">Included studies</h4> <p>The 20 included papers reported data from 17 unique studies. Of these, 10 compared topiramate with placebo (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0004" title="deTommasoM , GuidoM , SardaroM , SerpinoC , VecchioE , DeStefanoG , et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neuroscience Letters2008;442(2):81‐5. [MEDLINE: 18620023] deTommasoM , MarinazzoD , NittiL , PellicoroM , GuidoM , SerpinoC , et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clinical Neurophysiology2007;118(10):2297‐304. [MEDLINE: 17709295] ">de Tommaso 2007</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0006" title="DienerHC , AgostiR , AllaisG , BergmansP , BussoneG , DaviesB , et al. Cessation versus continuation of 6‐month migraine preventive therapy with topiramate (PROMPT): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2007;6(12):1054‐62. [MEDLINE: 17988947] ">Diener 2007</a>; <a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>; <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>), three directly compared different doses of topiramate (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>), and seven compared topiramate to another active intervention (<a href="./references#CD010610-bbs2-0001" title="AfshariD , RafizadehS , RezaeiM . A comparative study of the effects of low‐dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience2012;122(2):60‐8. [MEDLINE: 21950578] ">Afshari 2012</a>; <a href="./references#CD010610-bbs2-0002" title="AshtariF , ShaygannejadV , AkbariM . A double‐blind, randomized trial of low‐dose topiramate vs propranolol in migraine prophylaxis. Acta Neurologica Scandinavica2008;118(5):301‐5. [MEDLINE: 18713156] ">Ashtari 2008</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0007" title="DodickDW , FreitagF , BanksJ , SaperJ , XiangJ , RupnowM , et al. for the CAPSS‐277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26‐week, multicenter, randomized, double‐blind, double‐dummy, parallel‐group noninferiority trial in adult migraineurs. Clinical Therapeutics2009;31(3):542‐59. [MEDLINE: 19393844] ">Dodick 2009</a>; <a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a>; <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a>; <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>). </p> <p>Two trials (<a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>; <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a>) had a cross‐over design; the remaining 15 trials had a parallel‐group design. </p> <p>The doses of topiramate investigated ranged from 50 to 200 mg/day. This can be compared to the range of doses used in epilepsy, which is 200 to 400 mg. </p> <p>The duration of the treatment phase of the included trials varied from 4 to 52 weeks, with a mean of 19 weeks. </p> <p>See the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> for further details. </p> </section> <section id="CD010610-sec-0056"> <h4 class="title">Excluded studies</h4> <p>Of the 46 papers on topiramate obtained for full‐text scrutiny, 26 were excluded for reasons given in the <a href="./references#CD010610-sec-0110" title="">Characteristics of excluded studies</a> table. The most common reasons for exclusion were: review article/meta‐analysis (three papers), conference abstract only (three papers), and chronic migraine only (two papers). </p> </section> </section> <section id="CD010610-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>We scored methodological quality using the Jadad scale as indicated in the <a href="#CD010610-sec-0045">Assessment of risk of bias in included studies</a> section, with a maximum attainable score of 5. The median quality score was 3 (mean 3.6; range 2 to 5). </p> <p>Of 102 risk of bias items scored for the 17 studies, the majority of ratings were either 'unclear' (52 (51%)) or 'low' (38 (37%)) (<a href="#CD010610-fig-0001">Figure 1</a>; <a href="#CD010610-fig-0002">Figure 2</a>); we judged nine studies (<a href="./references#CD010610-bbs2-0001" title="AfshariD , RafizadehS , RezaeiM . A comparative study of the effects of low‐dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience2012;122(2):60‐8. [MEDLINE: 21950578] ">Afshari 2012</a>; <a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>; <a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a>; <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>; <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a>; <a href="./references#CD010610-bbs2-0015" title="SilbersteinSD , HulihanJ , KarimMR , WuSC , JordanD , KarvoisD , et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo‐controlled, double‐blind, 12‐week pilot study. Clinical Therapeutics2006;28(7):1002‐11. [MEDLINE: 16990078] ">Silberstein 2006</a>; <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>) as having a 'high' risk of bias for at least one item (<a href="#CD010610-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD010610-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010610-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD010610-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010610-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD010610-sec-0058"> <h4 class="title">Allocation</h4> <p>Fewer than half of the studies (<a href="#CD010610-fig-0002">Figure 2</a>) provided an adequate methodological description of how allocation sequences were generated. Most commonly this was achieved by a computer‐generated randomisation schedule, balanced by using permuted blocks and stratification by centre (see the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table). Likewise, fewer than half of the studies (<a href="#CD010610-fig-0002">Figure 2</a>) provided an adequate methodological description of attempts to conceal allocation of intervention assignment. One common method was to keep sealed envelopes containing preprinted medication code labels in a limited access area until subjects qualified for participation, although interactive voice response systems were also used (see the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table). A high risk of selection bias was valued for <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a> only. Given the open nature of that study, comparing topiramate to non‐pharmacological treatments, the high number of withdrawals in the topiramate arm suggests a predetermined treatment preference among randomised subjects and a 'refusal to start' using a prophylactic drug. </p> </section> <section id="CD010610-sec-0059"> <h4 class="title">Blinding</h4> <p>Participants and clinicians were blinded during the conduct of the majority of studies, but details of the methodology were reported for only five of them (see <a href="#CD010610-fig-0002">Figure 2</a> and the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table). Double‐blinding was typically achieved by packaging and labelling identical appearing tablets according to the randomisation codes. We judged four studies to have a high risk of performance bias. In <a href="./references#CD010610-bbs2-0001" title="AfshariD , RafizadehS , RezaeiM . A comparative study of the effects of low‐dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience2012;122(2):60‐8. [MEDLINE: 21950578] ">Afshari 2012</a> it is suspected that standard medications with different appearances were provided by a third party according to allocation label. In <a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>, placebo was identical in appearance and packaging to the active drug, but the lamotrigine and topiramate tablets were different in appearance, and therefore two different placebos were used. For effective blinding a double‐dummy design should have been used. <a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a> had an open‐label design. As <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a> compared pharmacological and non‐pharmacological treatments, blindness to treatment was not possible to achieve. Remarkably, that was the only paper clearly stating that the analyst was effectively blinded. The risk of detection bias in most studies (16 of 17; <a href="#CD010610-fig-0002">Figure 2</a>) is unclear. </p> </section> <section id="CD010610-sec-0060"> <h4 class="title">Incomplete outcome data</h4> <p>Completeness of data was adequately reported for nine of the 17 studies (<a href="#CD010610-fig-0002">Figure 2</a>). Usually an intention‐to‐treat (ITT) analysis was applied (see the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table). The review authors were particularly concerned over incomplete outcome data in <a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a> and <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>, which considered complete cases only. Furthermore, <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a> presented safety data for a vaguely defined subgroup of participants only. </p> </section> <section id="CD010610-sec-0061"> <h4 class="title">Selective reporting</h4> <p>We judged the risk of reporting bias as low in eight and unclear in five of the 17 studies (<a href="#CD010610-fig-0002">Figure 2</a>). A major obstacle to meta‐analysis was the lack of variance measures, as in both <a href="./references#CD010610-bbs2-0007" title="DodickDW , FreitagF , BanksJ , SaperJ , XiangJ , RupnowM , et al. for the CAPSS‐277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26‐week, multicenter, randomized, double‐blind, double‐dummy, parallel‐group noninferiority trial in adult migraineurs. Clinical Therapeutics2009;31(3):542‐59. [MEDLINE: 19393844] ">Dodick 2009</a> and <a href="./references#CD010610-bbs2-0015" title="SilbersteinSD , HulihanJ , KarimMR , WuSC , JordanD , KarvoisD , et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo‐controlled, double‐blind, 12‐week pilot study. Clinical Therapeutics2006;28(7):1002‐11. [MEDLINE: 16990078] ">Silberstein 2006</a> (see the <a href="./references#CD010610-sec-0109" title="">Characteristics of included studies</a> table). There were other concerns over the selective availability of data, including in: <a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>, which has never been published as a full report; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>, where ≥ 50% reduction in migraine days was investigated but only reported as "higher in the topiramate group compared with the placebo treatment group"; and <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a>, where only two types of adverse events were reported for the topiramate‐treated participants. </p> </section> <section id="CD010610-sec-0062"> <h4 class="title">Other potential sources of bias</h4> <p>Statistically significant results are more likely to be published than trials affirming a null result. This tendency for negative or inconclusive results to remain unpublished is inherently problematic also in the context of this review. Also, of eight corresponding authors whom we contacted and asked to provide supplementary unpublished information, only four responded with the requested information. Although it is unlikely that the requested input would have changed the conclusions of this review, the authors' support in clarifying reporting issues would undoubtedly have increased the quality and robustness of this review. </p> </section> </section> <section id="CD010610-sec-0063"> <h3 class="title" id="CD010610-sec-0063">Effects of interventions</h3> <section id="CD010610-sec-0064"> <h4 class="title">Topiramate versus placebo</h4> <section id="CD010610-sec-0065"> <h5 class="title">Methodological considerations</h5> <p>Significant statistical heterogeneity was evident across trials for the efficacy outcomes. The clinical similarity of trials was therefore examined to determine whether studies should be combined for statistical meta‐analysis. Although there was methodological variation as described above (<a href="#CD010610-sec-0057">Risk of bias in included studies</a>), the included trials were fundamentally similar with regard to basic design, patients, and measures. Note that three trials compared different doses of topiramate with placebo (50 mg, 100 mg, and 200 mg/day in <a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a> and <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>, and 100 mg and 200 mg/day in <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>). In the combined analyses, these trials have contributed data only for the dose judged by trial investigators to be most clinically advisable (100 mg/day in each case). Complete data for all three doses are considered below in separate analyses. </p> <p>All doses reported below are given in terms of mg/day.</p> </section> <section id="CD010610-sec-0066"> <h5 class="title">Headache frequency</h5> <p>Nine trials of topiramate (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0004" title="deTommasoM , GuidoM , SardaroM , SerpinoC , VecchioE , DeStefanoG , et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neuroscience Letters2008;442(2):81‐5. [MEDLINE: 18620023] deTommasoM , MarinazzoD , NittiL , PellicoroM , GuidoM , SerpinoC , et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clinical Neurophysiology2007;118(10):2297‐304. [MEDLINE: 17709295] ">de Tommaso 2007</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0006" title="DienerHC , AgostiR , AllaisG , BergmansP , BussoneG , DaviesB , et al. Cessation versus continuation of 6‐month migraine preventive therapy with topiramate (PROMPT): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2007;6(12):1054‐62. [MEDLINE: 17988947] ">Diener 2007</a>; <a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>; 1737 patients (one study had 56 cross‐over patients)) showed a significant reduction in headache frequency (per 28‐day period) in the active group compared to the placebo group in the combined analysis (mean difference (MD) ‐1.20; 95% confidence interval (CI) ‐1.59 to ‐0.80; <a href="#CD010610-fig-0003">Figure 3</a>). It should be noted that two of these trials (<a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>) reported significant reductions in migraine frequency in the active treatment group (topiramate 200 mg) compared to placebo, using analysis of covariance to control for baseline differences in frequency; by contrast, our analysis of the post‐treatment mean headache frequencies showed no statistically significant differences (<a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>: MD ‐1.29; 95% CI ‐3.56 to 0.98; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>: MD ‐0.52; 95% CI ‐1.67 to 0.63). Separate analyses of all the data on the three topiramate doses studied (<a href="#CD010610-fig-0004">Figure 4</a>) suggest similar MDs versus placebo for 50 mg (‐0.95; 95% CI ‐1.95 to 0.04; three studies; 520 participants (one study had 56 cross‐over patients)), 100 mg (‐1.15; 95% CI ‐1.58 to ‐0.71; six studies; 1620 participants), and 200 mg doses (‐0.94; 95% CI ‐1.53 to ‐0.36; five studies; 804 participants). </p> <div class="figure" id="CD010610-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> </div> <div class="figure" id="CD010610-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 Topiramate (separate analyses of various doses) versus placebo, outcome: 2.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 Topiramate (separate analyses of various doses) versus placebo, outcome: 2.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> </div> <p>In clinical terms, the difference in effect between topiramate and placebo observed in the combined analysis (<a href="#CD010610-fig-0003">Figure 3</a>) corresponds to a reduction in headache frequency of a little more than one headache per 28 days. The median baseline headache frequency in the topiramate groups of the placebo‐controlled trials was 5.6 attacks per 28 days (mean 7.0; range: 4.8 to 11.6). </p> </section> <section id="CD010610-sec-0067"> <h5 class="title">Responders (patients with ≥ 50% reduction in headache frequency)</h5> <p>In the combined analysis of nine trials (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0004" title="deTommasoM , GuidoM , SardaroM , SerpinoC , VecchioE , DeStefanoG , et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neuroscience Letters2008;442(2):81‐5. [MEDLINE: 18620023] deTommasoM , MarinazzoD , NittiL , PellicoroM , GuidoM , SerpinoC , et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clinical Neurophysiology2007;118(10):2297‐304. [MEDLINE: 17709295] ">de Tommaso 2007</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>; <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>; <a href="./references#CD010610-bbs2-0015" title="SilbersteinSD , HulihanJ , KarimMR , WuSC , JordanD , KarvoisD , et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo‐controlled, double‐blind, 12‐week pilot study. Clinical Therapeutics2006;28(7):1002‐11. [MEDLINE: 16990078] ">Silberstein 2006</a>; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>; 1190 participants (one study had 56 cross‐over patients)) topiramate demonstrated overall superiority of treatment to placebo in the proportion of responders (odds ratio (OR) 3.18; 95% CI 2.10 to 4.82; <a href="./references#CD010610-fig-0007" title="">Analysis 1.2</a>), although there was noticeable variability in the ORs across studies. Separate analysis of all the data on the various topiramate doses studied (<a href="./references#CD010610-fig-0010" title="">Analysis 2.2</a>) showed that all three (50, 100, and 200 mg) significantly increased the proportion of responders. ORs were as follows: for 50 mg, 2.35 (95% CI 1.60 to 3.44; three studies; 520 participants (one study had 56 cross‐over participants)); for 100 mg, 3.49 (95% CI 2.23 to 5.45; five studies; 852 participants); and for 200 mg, 2.49 (95% CI 1.61 to 3.87; six studies; 1025 participants). </p> <p>In clinical terms, the effect observed in the combined analysis suggests that patients are twice as likely to experience a ≥ 50% reduction in frequency with topiramate as with placebo. Details are as follows: </p> <p> <ul id="CD010610-list-0004"> <li> <p>The proportion of responders with topiramate was 47% (310/660; range: 26% to 63%);</p> </li> <li> <p>The proportion of responders with placebo was 23% (136/586; range 0% to 34%);</p> </li> <li> <p>The risk ratio (RR) for topiramate versus placebo was 2.02 (95% CI 1.57 to 2.60) (<a href="#CD010610-fig-0005">Figure 5</a>); </p> </li> <li> <p>The number needed to treat (NNT) for topiramate versus placebo was 4 (95% CI 3 to 6). </p> </li> </ul> </p> <div class="figure" id="CD010610-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.3 RRs for responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.3 RRs for responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> </div> </section> <section id="CD010610-sec-0068"> <h5 class="title">Quality of life</h5> <p>Two studies (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>) reported data on patient‐reported quality of life as measured by the Migraine‐Specific Questionnaire (MSQ) (three domains) and the Medical Outcomes Study 36‐item Short‐Form Health Survey (SF‐36) (eight domains). In the combined analyses of topiramate 50 mg versus placebo (463 participants), a significant difference was found for 3 of 11 domains: MSQ‐role function restrictive (<a href="./references#CD010610-fig-0019" title="">Analysis 2.11</a>), MSQ‐emotional function (<a href="./references#CD010610-fig-0021" title="">Analysis 2.13</a>), and SF‐36 bodily pain (<a href="./references#CD010610-fig-0025" title="">Analysis 2.17</a>), all favouring topiramate 50 mg. In the combined analyses of topiramate 100 mg versus placebo (474 participants), a significant difference was again found for 3 of 11 domains: MSQ‐role function restrictive (<a href="./references#CD010610-fig-0019" title="">Analysis 2.11</a>), MSQ‐role function prevention (<a href="./references#CD010610-fig-0020" title="">Analysis 2.12</a>), and MSQ‐emotional function (<a href="./references#CD010610-fig-0021" title="">Analysis 2.13</a>), all favouring topiramate 100 mg. In the combined analyses of topiramate 200 mg versus placebo (458 participants), a significant difference was found for 4 of 11 domains: MSQ‐role function restrictive (<a href="./references#CD010610-fig-0019" title="">Analysis 2.11</a>), MSQ‐role function prevention (<a href="./references#CD010610-fig-0020" title="">Analysis 2.12</a>), MSQ‐emotional function (<a href="./references#CD010610-fig-0021" title="">Analysis 2.13</a>), and SF‐36 role physical (<a href="./references#CD010610-fig-0022" title="">Analysis 2.14</a>), all favouring topiramate 200 mg. </p> <p>In summary, the disease‐specific MSQ found better quality of life on topiramate than on placebo, but the generic SF‐36 was more equivocal (only 2 of 24 analyses pointed in this direction). </p> </section> </section> <section id="CD010610-sec-0069"> <h4 class="title">Direct dose comparisons</h4> <p>Three studies directly compared different doses of topiramate and reported data on headache frequency (<a href="./references#CD010610-fig-0030" title="">Analysis 3.1</a>) and responders (<a href="./references#CD010610-fig-0031" title="">Analysis 3.2</a>). Data from <a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a> and <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a> were used to compare all three doses of topiramate, with additional data from <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a> contributing to the comparison between 200 mg and 100 mg. The 200 mg dose was significantly superior to 50 mg both in terms of reducing headache frequency (MD ‐0.96; 95% CI ‐1.53 to ‐0.40; 463 participants) and increasing the proportion of responders (OR 1.66; 95% CI 1.15 to 2.41; 462 participants). Likewise, 100 mg was superior to 50 mg (MD ‐0.71; 95% CI ‐1.32 to ‐0.10 (479 participants); and OR 1.80; 95% CI 1.25 to 2.60 (478 participants)). The 200 mg dose was not significantly superior to 100 mg for either outcome measure (756 participants). </p> <p>Two studies (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a> and <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>) directly comparing different doses of topiramate reported data on patient‐reported quality of life as measured by the MSQ (three domains) and SF‐36 (eight domains). In the combined analyses of topiramate 50 mg versus 100 mg (479 participants), a significant difference was found for 3 of 11 domains: MSQ‐role function restrictive (<a href="./references#CD010610-fig-0032" title="">Analysis 3.3</a>), MSQ‐role function prevention (<a href="./references#CD010610-fig-0033" title="">Analysis 3.4</a>), and MSQ‐emotional function (<a href="./references#CD010610-fig-0034" title="">Analysis 3.5</a>), all favouring the higher dose. In the combined analyses of topiramate 50 mg versus 200 mg (463 participants), a significant difference was found for only 1 of 11 domains: MSQ‐role function restrictive (<a href="./references#CD010610-fig-0032" title="">Analysis 3.3</a>), favouring the higher dose. In the combined analyses of topiramate 100 mg versus 200 mg (474 participants), a significant difference was found for only 1 of 11 domains: SF‐36 physical functioning (<a href="./references#CD010610-fig-0037" title="">Analysis 3.8</a>), favouring the lower dose. </p> <p>It is important to note, however, that none of these studies was designed to have the statistical power to make comparisons between doses. </p> </section> <section id="CD010610-sec-0070"> <h4 class="title">Topiramate versus active comparators</h4> <p>Seven trials examined topiramate versus active comparators, including:</p> <p> <ul id="CD010610-list-0005"> <li> <p>amitriptyline (one study, 330 participants);</p> </li> <li> <p>flunarizine (one study, 83 participants);</p> </li> <li> <p>propranolol (two studies, 342 participants);</p> </li> <li> <p>sodium valproate (two studies, 120 participants);</p> </li> <li> <p>relaxation (one study, 61 participants).</p> </li> </ul> </p> <p><a href="./references#CD010610-bbs2-0007" title="DodickDW , FreitagF , BanksJ , SaperJ , XiangJ , RupnowM , et al. for the CAPSS‐277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26‐week, multicenter, randomized, double‐blind, double‐dummy, parallel‐group noninferiority trial in adult migraineurs. Clinical Therapeutics2009;31(3):542‐59. [MEDLINE: 19393844] ">Dodick 2009</a> compared topiramate to amitriptyline (both drugs titrated to maximum tolerated dose between 50 and 100 mg). Data were insufficient for us to calculate MDs for headache frequency, our preferred outcome measure. There was no significant difference between treatments in the proportion of responders (OR 0.68; 95% CI 0.44 to 1.05; 330 participants; <a href="./references#CD010610-fig-0043" title="">Analysis 4.1</a>) or in the change from baseline in Migraine Disability Assessment (MIDAS) scores (MD 2.10; 95% CI ‐2.93 to 7.13; 295 participants; <a href="./references#CD010610-fig-0044" title="">Analysis 4.2</a>). </p> <p>One small, open study (<a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a>) compared topiramate titrated to 100 mg (or lower if lack of tolerance) to flunarizine 5 mg. There was no significant difference in mean headache frequency during treatment (MD 0.30; 95% CI ‐0.37 to 0.97; 83 participants; <a href="./references#CD010610-fig-0045" title="">Analysis 5.1</a>) or in the proportion of responders (OR 0.83; 95% CI 0.34 to 2.03; 83 participants; <a href="./references#CD010610-fig-0046" title="">Analysis 5.2</a>). It should be noted that the flunarizine dose used in this study (5 mg) is in the lower range of doses used in routine clinical practice (5 to 10 mg). </p> <p>In a comparison between topiramate 50 mg and propranolol 80 mg, <a href="./references#CD010610-bbs2-0002" title="AshtariF , ShaygannejadV , AkbariM . A double‐blind, randomized trial of low‐dose topiramate vs propranolol in migraine prophylaxis. Acta Neurologica Scandinavica2008;118(5):301‐5. [MEDLINE: 18713156] ">Ashtari 2008</a> did not demonstrate a significant difference in mean headache frequency during treatment (MD ‐0.37; 95% CI ‐1.15 to 0.41; 60 participants; <a href="./references#CD010610-fig-0047" title="">Analysis 6.1</a>). In a larger study, <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a> included an additional arm (propranolol 160 mg) in a trial of topiramate (200 mg and 100 mg) versus placebo. A comparison of propranolol with topiramate 100 mg (the dose judged by trial investigators to be most clinically advisable) showed no significant difference in the change in headache frequency from baseline (MD 0.00; 95% CI ‐0.60 to 0.60; 282 participants; <a href="./references#CD010610-fig-0047" title="">Analysis 6.1</a>) or in the proportion of responders (OR 1.32; 95% CI 0.82 to 2.13; 282 participants; <a href="./references#CD010610-fig-0048" title="">Analysis 6.2</a>). The pooled results of these two studies do not indicate a significant difference between topiramate and propranolol with regard to headache frequency (MD ‐0.14; 95% CI ‐0.61 to 0.34; 342 participants; <a href="./references#CD010610-fig-0047" title="">Analysis 6.1</a>). </p> <p>Two fairly small studies compared topiramate 50 mg with sodium valproate 400 mg. <a href="./references#CD010610-bbs2-0001" title="AfshariD , RafizadehS , RezaeiM . A comparative study of the effects of low‐dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience2012;122(2):60‐8. [MEDLINE: 21950578] ">Afshari 2012</a> did not demonstrate a significant difference in mean headache frequency during treatment (MD ‐0.60; 95% CI ‐1.57 to 0.37; 56 participants; <a href="./references#CD010610-fig-0049" title="">Analysis 7.1</a>) or in MIDAS score during the treatment phase (MD ‐3.90; 95% CI ‐8.72 to 0.92; 56 participants; <a href="./references#CD010610-fig-0050" title="">Analysis 7.2</a>). On the basis of their statistical analysis, the authors of <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a> found no significant differences in efficacy between the two drugs. However, our analysis of post‐treatment mean headache frequencies demonstrated a slight but significant advantage for topiramate over valproate (MD ‐1.20; 95% CI ‐2.16 to ‐0.24; 32 (cross‐over) participants; <a href="./references#CD010610-fig-0049" title="">Analysis 7.1</a>). The pooled results of these two studies indicate a significant difference between topiramate and sodium valproate, in favour of topiramate, for this outcome (MD ‐0.90; 95% CI ‐1.58 to ‐0.22; <a href="./references#CD010610-fig-0049" title="">Analysis 7.1</a>). In clinical terms, the observed effect corresponds to a reduction in headache frequency of approximately one headache per 28 days with topiramate versus sodium valproate. The median baseline headache frequency in the topiramate groups of the two trials was 6.1 headaches per 28 days (mean 6.1; range: 5.4 to 6.8). It should be noted that the doses used in these two studies are not those used in routine clinical practice for the management of migraine. </p> <p>In a small, open study, <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a> compared topiramate (200 mg or maximum tolerated dose &lt; 200 mg) to relaxation and found no significant difference in the change in headache frequency from baseline (MD ‐0.14; 95% CI ‐0.30 to 0.02; 61 participants; <a href="./references#CD010610-fig-0051" title="">Analysis 8.1</a>) or in the proportion of responders (OR 0.88; 95% CI 0.27 to 2.81; 61 participants; <a href="./references#CD010610-fig-0052" title="">Analysis 8.2</a>). There was a significant difference in the change of quality of life (Migraine‐Specific Quality of Life Questionnaire (MSQoL), 0 to 100 points) from baseline (MD ‐1.50; 95% CI ‐2.45 to ‐0.55; 61 participants; <a href="./references#CD010610-fig-0053" title="">Analysis 8.3</a>), favouring relaxation. As discussed above (<a href="#CD010610-sec-0059">Blinding (performance bias and detection bias)</a>), there was a high risk of selection bias in this trial. </p> </section> <section id="CD010610-sec-0071"> <h4 class="title">Safety</h4> <p>During the process of extracting safety data, it became clear that the range of adverse events (AEs) and the method of their reporting varied very considerably from trial to trial. In the nine trials of topiramate versus placebo, seven specific adverse events were reported by at least three trials. We calculated risk differences (RDs) separately for the various doses of topiramate (50 mg, 100 mg, and 200 mg) versus placebo for any adverse event (<a href="./references#CD010610-fig-0011" title="">Analysis 2.3</a>), anorexia (<a href="./references#CD010610-fig-0012" title="">Analysis 2.4</a>), fatigue (<a href="./references#CD010610-fig-0013" title="">Analysis 2.5</a>), memory problems (<a href="./references#CD010610-fig-0014" title="">Analysis 2.6</a>), nausea (<a href="./references#CD010610-fig-0015" title="">Analysis 2.7</a>), paresthesia (<a href="./references#CD010610-fig-0016" title="">Analysis 2.8</a>), taste disturbance (<a href="./references#CD010610-fig-0017" title="">Analysis 2.9</a>), and weight loss (<a href="./references#CD010610-fig-0018" title="">Analysis 2.10</a>). We then calculated numbers needed to harm (NNHs) and 95% CIs where appropriate, and these are reported in <a href="#CD010610-tbl-0001">Table 1</a>. Except for taste disturbance (<a href="./references#CD010610-fig-0017" title="">Analysis 2.9</a>) and weight loss (<a href="./references#CD010610-fig-0018" title="">Analysis 2.10</a>), there were no significant differences in the frequency of AEs in general or of the individual AEs between placebo and topiramate 50 mg. All AEs except nausea were significantly more common with topiramate 100 mg than with placebo, with NNHs varying from 3 to 25, and the RDs were even higher for topiramate 200 mg versus placebo, with NNHs varying from 2 to 17 (<a href="#CD010610-tbl-0001">Table 1</a>). RDs were generally smaller in <a href="./references#CD010610-bbs2-0006" title="DienerHC , AgostiR , AllaisG , BergmansP , BussoneG , DaviesB , et al. Cessation versus continuation of 6‐month migraine preventive therapy with topiramate (PROMPT): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2007;6(12):1054‐62. [MEDLINE: 17988947] ">Diener 2007</a>, which is logical considering its design, with an initial open‐label phase (with a possibility to withdraw or adjust dosage due to AEs), followed by randomisation to the double‐blind, parallel‐group phase of prolonged topiramate treatment at individualised dose or placebo. </p> <div class="table" id="CD010610-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">NNHs (with 95% CIs), by dose, for placebo‐controlled trials of topiramate and proportion of withdrawals in trials with active intervention or placebo as control</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of AE</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 mg/day</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 mg/day</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>200 mg/day</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (7 to 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3 to 12)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (10 to 50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (8 to 20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (17 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (8 to 25)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (17 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (9 to 17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (9 to 50)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paresthesia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (2 to 3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taste disturbance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (5 to 14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (8 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (5 to 11)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (14 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (11 to 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (8 to 14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of patients in active group withdrawing because of AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Afshari 2012: 5%; Ashtari 2008: 3%; Brandes 2004: 17%; Gupta 2007: 2%; Silberstein 2004: 17% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brandes 2004: 26%; de Tommaso 2007: 8%; Diener 2004: 28%; Dodick 2009: 20%; Lipton 2011: 12%; Mei 2004: 29%; Silberstein 2004: 19% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brandes 2004: 21%; Diener 2004: 44%; Edwards 2000: 27%; Silberstein 2004: 32%; Silberstein 2006: 15%; Storey 2001: 11%; Varkey 2011: 12% </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* The 95% CI of the difference in AE rates between treatment and placebo arms (the risk difference, RD) crosses zero. </p> <p>Abbreviations: AE = adverse event; CI = confidence interval; NNH = number needed to harm </p> </div> </div> <p><a href="#CD010610-tbl-0001">Table 1</a> also reports, by dose, the percentages of patients in active treatment groups who withdrew because of AEs in each trial. The mean percentage withdrawing because of AEs at 100 mg was 20%. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010610-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010610-sec-0072"></div> <section id="CD010610-sec-0073"> <h3 class="title" id="CD010610-sec-0073">Summary of main results</h3> <section id="CD010610-sec-0074"> <h4 class="title">Placebo‐controlled trials</h4> <p>Meta‐analysis of the studies included in this review demonstrates clearly that topiramate is efficacious for the prophylaxis of migraine. Mean headache frequency was significantly reduced (by approximately 1.2 headaches per month) with topiramate as compared to placebo (nine studies with a median baseline headache frequency of 5.6 attacks per 28 days contributed to this analysis). Furthermore, and perhaps of greater clinical relevance (though less informative scientifically), patients were approximately twice as likely to have a ≥ 50% reduction in headache frequency with topiramate than with placebo (nine studies contributed to this analysis). </p> <p>According to two large trials (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>), topiramate 50 mg gives rise to a significant increase in the proportion of responders (patients with ≥ 50% reduction in headache frequency), but not to a significant overall decrease in monthly headache frequency. In contrast, one small trial (<a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>) found superiority over placebo of topiramate 50 mg both with regard to reduction of headache frequency and responder rate. </p> <p>All included trials comparing topiramate 100 mg to placebo (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0004" title="deTommasoM , GuidoM , SardaroM , SerpinoC , VecchioE , DeStefanoG , et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neuroscience Letters2008;442(2):81‐5. [MEDLINE: 18620023] deTommasoM , MarinazzoD , NittiL , PellicoroM , GuidoM , SerpinoC , et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clinical Neurophysiology2007;118(10):2297‐304. [MEDLINE: 17709295] ">de Tommaso 2007</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0006" title="DienerHC , AgostiR , AllaisG , BergmansP , BussoneG , DaviesB , et al. Cessation versus continuation of 6‐month migraine preventive therapy with topiramate (PROMPT): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2007;6(12):1054‐62. [MEDLINE: 17988947] ">Diener 2007</a>; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>; <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>) showed unambiguous statistically significant superiority of topiramate, although one study did not report data enabling a comparison of reduction of headache frequency (<a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>), and two studies (<a href="./references#CD010610-bbs2-0006" title="DienerHC , AgostiR , AllaisG , BergmansP , BussoneG , DaviesB , et al. Cessation versus continuation of 6‐month migraine preventive therapy with topiramate (PROMPT): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2007;6(12):1054‐62. [MEDLINE: 17988947] ">Diener 2007</a>; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>) did not report data enabling a comparison of the proportion of responders. </p> <p>The four large trials comparing topiramate 200 mg to placebo were equivocal in that all showed a statistically significant superiority for topiramate with regard to the responder rate, whereas only two studies (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>) also showed a statistically significant difference in reduction of headache frequency, while two do not (<a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>; <a href="./references#CD010610-bbs2-0015" title="SilbersteinSD , HulihanJ , KarimMR , WuSC , JordanD , KarvoisD , et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo‐controlled, double‐blind, 12‐week pilot study. Clinical Therapeutics2006;28(7):1002‐11. [MEDLINE: 16990078] ">Silberstein 2006</a>). In two additional small trials of topiramate 200 mg (<a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>), the analysis for headache frequency did not reveal a significant difference versus placebo in either study, although one trial reported topiramate 200 mg to be significantly more efficacious for responder rates (<a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>). </p> <p>Based on the combined analyses of two studies (<a href="./references#CD010610-bbs2-0003" title="BrandesJL , KudrowDB , RothrockJF , RupnowMFT , FaircloughDL , GreenbergSJ . Assessing the ability of topiramate to improve the daily activities of patients with migraine. Mayo Clinic Proceedings2006;81(10):1311‐9. [MEDLINE: 17036556] BrandesJL , SaperJR , DiamondM , CouchJR , LewisDW , SchmittJ , et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA2004;291(8):965‐73. [MEDLINE: 14982912] ">Brandes 2004</a>; <a href="./references#CD010610-bbs2-0014" title="SilbersteinSD , LoderE , FordeG , PapadopoulosG , FaircloughD , GreenbergS . The impact of migraine on daily activities: effect of topiramate compared with placebo. Current Medical Research &amp; Opinion2006;22(6):1021‐9. [MEDLINE: 16846536] SilbersteinSD , NetoW , SchmittJ , JacobsD , for the MIGR‐001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Archives of Neurology2004;61(4):490‐5. [MEDLINE: 15096395] ">Silberstein 2004</a>), all three doses of topiramate significantly improved three or more domains of quality of life as compared to placebo. </p> </section> <section id="CD010610-sec-0075"> <h4 class="title">Dose comparisons</h4> <p>The studies including more than one dose of topiramate suggest that 200 mg is no more effective than 100 mg. </p> </section> <section id="CD010610-sec-0076"> <h4 class="title">Trials with active comparators</h4> <p>With regard to reduction of mean headache frequency and/or responder rate, the six trials using active comparators found (a) no significant difference in efficacy between topiramate and amitriptyline (<a href="./references#CD010610-bbs2-0007" title="DodickDW , FreitagF , BanksJ , SaperJ , XiangJ , RupnowM , et al. for the CAPSS‐277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26‐week, multicenter, randomized, double‐blind, double‐dummy, parallel‐group noninferiority trial in adult migraineurs. Clinical Therapeutics2009;31(3):542‐59. [MEDLINE: 19393844] ">Dodick 2009</a>); (b) no significant difference in efficacy between topiramate and flunarizine; (c) no significant difference in efficacy between topiramate and propranolol (<a href="./references#CD010610-bbs2-0002" title="AshtariF , ShaygannejadV , AkbariM . A double‐blind, randomized trial of low‐dose topiramate vs propranolol in migraine prophylaxis. Acta Neurologica Scandinavica2008;118(5):301‐5. [MEDLINE: 18713156] ">Ashtari 2008</a>; <a href="./references#CD010610-bbs2-0005" title="DienerHC , Tfelt‐HansenP , DahlöfC , LainezMJA , SandriniG , WangSJ , et al. Topiramate in migraine prophylaxis: results from a placebo‐controlled trial with propranolol as an active control. Journal of Neurology2004;251(8):943‐50. [MEDLINE: 15316798] ">Diener 2004</a>); (d) no significant difference in efficacy between topiramate and relaxation (<a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>); (e) a slight significant advantage of topiramate over valproate (pooled results of <a href="./references#CD010610-bbs2-0001" title="AfshariD , RafizadehS , RezaeiM . A comparative study of the effects of low‐dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience2012;122(2):60‐8. [MEDLINE: 21950578] ">Afshari 2012</a> and <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a>). Furthermore, relaxation increased migraine‐specific quality of life significantly more than topiramate (<a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>). However, only three of these seven studies (<a href="./references#CD010610-bbs2-0006" title="DienerHC , AgostiR , AllaisG , BergmansP , BussoneG , DaviesB , et al. Cessation versus continuation of 6‐month migraine preventive therapy with topiramate (PROMPT): a randomised, double‐blind, placebo‐controlled trial. Lancet Neurology2007;6(12):1054‐62. [MEDLINE: 17988947] ">Diener 2007</a>, 95%; <a href="./references#CD010610-bbs2-0007" title="DodickDW , FreitagF , BanksJ , SaperJ , XiangJ , RupnowM , et al. for the CAPSS‐277 Investigator Group. Topiramate versus amitriptyline in migraine prevention: a 26‐week, multicenter, randomized, double‐blind, double‐dummy, parallel‐group noninferiority trial in adult migraineurs. Clinical Therapeutics2009;31(3):542‐59. [MEDLINE: 19393844] ">Dodick 2009</a>, 85%; <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>, 80%) reported adequate power; the others were likely to have been underpowered. </p> </section> <section id="CD010610-sec-0077"> <h4 class="title">Safety</h4> <p>Topiramate does not appear to give rise to an unexpectedly high rate of adverse events when used for migraine prophylaxis, although a large percentage of patients taking topiramate report paresthesia. Withdrawals due to adverse events were somewhat higher in trials of topiramate than would generally be expected on the basis of trials of other antiepileptic drugs, particularly sodium valproate or divalproex sodium. </p> </section> </section> <section id="CD010610-sec-0078"> <h3 class="title" id="CD010610-sec-0078">Overall completeness and applicability of evidence</h3> <p>The studies identified were sufficient to address all of the objectives of the review. Our analysis demonstrates that topiramate is efficacious for preventing attacks in adult patients with episodic migraine, and these results fit into the context of current practice. Since the comparisons with flunarizine and valproate were in all probability underpowered, the evidence from these is incomplete. The trials comparing topiramate with amitriptyline and propranolol are of relevance since both these drugs have proven efficacy in the prophylaxis of migraine. The trial comparing topiramate with relaxation is also interesting. Further well‐designed trials of topiramate against other drug categories and non‐pharmacological interventions are desirable. </p> <p>Several important issues need to be taken into account in any assessment of the efficacy of a drug for migraine prophylaxis. Diagnostic criteria, baseline headache frequency, washout periods for previous medication, rules for rescue medication, and the statistical power of the comparison were handled very variably in the 17 included studies. As investigations of the efficacy of various agents become more commonplace, it seems increasingly important that scientists and clinicians are at least aware of the trial guidelines suggested by the International Headache Society (<a href="./references#CD010610-bbs2-0068" title="Tfelt‐HansenP , PascualJ , RamadanN , DahlöfC , D'AmicoD , DienerHC , et al. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia2012;32(1):6‐38. [MEDLINE: 22384463] ">Tfelt‐Hansen 2012</a>). Even if these guidelines cannot — for operational or scientific reasons — be adhered to in their entirety, they provide a useful consultative framework at the early stages of trial design. </p> </section> <section id="CD010610-sec-0079"> <h3 class="title" id="CD010610-sec-0079">Quality of the evidence</h3> <p>The identified body of evidence allows a robust conclusion of an overall superiority of topiramate over placebo with regard to reduction of mean headache frequency (nine trials with 1737 participants) and the proportion of responders (nine trials with 1190 participants). The separate analyses of doses should, however, be viewed with some caution. Several of the included trials were almost certainly underpowered (<a href="./references#CD010610-bbs2-0004" title="deTommasoM , GuidoM , SardaroM , SerpinoC , VecchioE , DeStefanoG , et al. Effects of topiramate and levetiracetam vs placebo on habituation of contingent negative variation in migraine patients. Neuroscience Letters2008;442(2):81‐5. [MEDLINE: 18620023] deTommasoM , MarinazzoD , NittiL , PellicoroM , GuidoM , SerpinoC , et al. Effects of levetiracetam vs topiramate and placebo on visually evoked phase synchronization changes of alpha rhythm in migraine. Clinical Neurophysiology2007;118(10):2297‐304. [MEDLINE: 17709295] ">de Tommaso 2007</a>; <a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0016" title="StoreyJR , CalderCS , HartDE , PotterDL . Topiramate in migraine prevention: a double‐blind, placebo‐controlled study. Headache2001;41(10):968‐75. [MEDLINE: 11903524] ">Storey 2001</a>). The studies including more than one dose of topiramate were generally not designed to enable direct dose comparisons, and the results of the dose comparisons reported here should therefore be viewed with some caution. It should be noted that all seven trials with active comparators are potentially problematic for reasons including lack of blinding, insufficient statistical power, and possibly incomplete statistical analysis. As usual in the context of clinical trials research, there was considerable heterogeneity in both headline results and general levels of analytical and statistical sophistication. It is fair to say that we faced several difficulties in deriving adequate information from the results of the 17 included studies. First, means and standard deviations were not always fully reported for each phase of trials. In tandem with this problem, reported measures of variability — either appearing in the text, tabulated, or as error bars in graphs — were not always adequately described or labelled. Second, methods of statistical analysis were generally under‐specified, leading in some cases to a lack of clarity as to which comparisons were significant and which were not. Third, there was considerable variability in how intention‐to‐treat analyses were performed. In a few cases, this gave rise to uncertainty about the numbers of patients continuing to each phase of the trial. </p> </section> <section id="CD010610-sec-0080"> <h3 class="title" id="CD010610-sec-0080">Potential biases in the review process</h3> <p>Of 102 risk of bias items scored for the 17 studies, the majority of ratings were either 'unclear' (52 (51%)) or 'low' (38 (37%)) (<a href="#CD010610-fig-0001">Figure 1</a>; <a href="#CD010610-fig-0002">Figure 2</a>). As described in detail above (<a href="#CD010610-sec-0057">Risk of bias in included studies</a>), we judged nine trials as having a 'high' risk of bias for at least one item, as follows: allocation concealment (<a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>), blinding of participants and personnel (<a href="./references#CD010610-bbs2-0001" title="AfshariD , RafizadehS , RezaeiM . A comparative study of the effects of low‐dose topiramate versus sodium valproate in migraine prophylaxis. International Journal of Neuroscience2012;122(2):60‐8. [MEDLINE: 21950578] ">Afshari 2012</a>; <a href="./references#CD010610-bbs2-0009" title="GuptaP , SinghS , GoyalV , ShuklaG , BehariM . Low‐dose topiramate versus lamotrigine in migraine prophylaxis (the Lotolamp study). Headache2007;47(3):402‐12. [MEDLINE: 17371357] ">Gupta 2007</a>; <a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a>; <a href="./references#CD010610-bbs2-0017" title="VarkeyE , CiderÅ , CarlssonJ , LindeM . Exercise as migraine prophylaxis: a randomized study using relaxation and topiramate as controls. Cephalalgia2011;31(14):1428‐38. [MEDLINE: 21890526] ">Varkey 2011</a>), incomplete outcome data (<a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0011" title="LuoN , DiW , ZhangA , WangY , DingM , QiW , et al. A randomized, one‐year clinical trial comparing the efficacy of topiramate, flunarizine, and a combination of flunarizine and topiramate in migraine prophylaxis. Pain Medicine2012;13(1):80‐6. [MEDLINE: 22233396] ">Luo 2012</a>; <a href="./references#CD010610-bbs2-0012" title="MeiD , CapuanoA , VollonoC , EvangelistaM , FerraroD , TonaliP , et al. Topiramate in migraine prophylaxis: a randomised double‐blind versus placebo study. Neurological Sciences2004;25(5):245‐50. [MEDLINE: 15624081] ">Mei 2004</a>), and/or selective reporting (<a href="./references#CD010610-bbs2-0008" title="EdwardsKR , GlantzMJ , NortonJA , CrossN . Prophylactic treatment of episodic migraine with topiramate: a double‐blind, placebo‐controlled trial in 30 patients. Cephalalgia2000;20(4):316. [DOI: 10.1046/j.1468‐2982.2000.00204.x] ">Edwards 2000</a>; <a href="./references#CD010610-bbs2-0010" title="LiptonRB , SilbersteinS , DodickD , CadyR , FreitagF , MathewN , et al. Topiramate intervention to prevent transformation of episodic migraine: the topiramate INTREPID study. Cephalalgia2011;31(1):18‐30. [MEDLINE: 20974598] ">Lipton 2011</a>; <a href="./references#CD010610-bbs2-0013" title="ShaygannejadV , JanghorbaniM , GhorbaniA , AshtaryF , ZakizadeN , NasrV . Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache2006;46(4):642‐8. [MEDLINE: 16643559] ">Shaygannejad 2006</a>; <a href="./references#CD010610-bbs2-0015" title="SilbersteinSD , HulihanJ , KarimMR , WuSC , JordanD , KarvoisD , et al. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo‐controlled, double‐blind, 12‐week pilot study. Clinical Therapeutics2006;28(7):1002‐11. [MEDLINE: 16990078] ">Silberstein 2006</a>). A strength of this review is that the methods used for searching and study selection make it highly likely that the absolute majority of relevant trial results in the public domain were identified. There is nevertheless an obvious risk that the reports of some trials may have been classified and thus remain unobtainable. </p> </section> <section id="CD010610-sec-0081"> <h3 class="title" id="CD010610-sec-0081">Agreements and disagreements with other studies or reviews</h3> <p>The overall conclusion in this review, that topiramate is efficacious for preventing attacks in adult patients with episodic migraine, is well in line with guideline recommendations of the European Federation of Neurological Societies (EFNS) (<a href="./references#CD010610-bbs2-0050" title="EversS , AfraJ , FreseA , GoadsbyPJ , LindeM , MayA , et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. European Journal of Neurology2009;16(9):968‐81. [MEDLINE: 19708964] ">Evers 2009</a>) and the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society (<a href="./references#CD010610-bbs2-0067" title="SilbersteinSD , HollandS , FreitagF , DodickDW , ArgoffC , AshmanE , Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence‐based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology2012;78(17):1337‐45. [MEDLINE: 22529202] ">Silberstein 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010610-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD010610-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD010610-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 Topiramate (separate analyses of various doses) versus placebo, outcome: 2.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0004" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 Topiramate (separate analyses of various doses) versus placebo, outcome: 2.1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.3 RRs for responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0005" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, outcome: 1.3 RRs for responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0006" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, Outcome 2 ORs for responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0007" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, Outcome 2 ORs for responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-001-03.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, Outcome 3 RRs for responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0008" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Topiramate (combined analyses based on most relevant dose in each study) versus placebo, Outcome 3 RRs for responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0009" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0010" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 3 Any adverse event." data-id="CD010610-fig-0011" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 3 Any adverse event. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 4 Anorexia." data-id="CD010610-fig-0012" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 4 Anorexia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 5 Fatigue." data-id="CD010610-fig-0013" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 5 Fatigue. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 6 Memory problems." data-id="CD010610-fig-0014" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 6 Memory problems. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 7 Nausea." data-id="CD010610-fig-0015" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 7 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 8 Paresthesia." data-id="CD010610-fig-0016" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 8 Paresthesia. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 9 Taste disturbance." data-id="CD010610-fig-0017" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 9 Taste disturbance. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 10 Weight loss." data-id="CD010610-fig-0018" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 10 Weight loss. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 11 MSQ‐role function restrictive." data-id="CD010610-fig-0019" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 11 MSQ‐role function restrictive. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 12 MSQ‐role function prevention." data-id="CD010610-fig-0020" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 12 MSQ‐role function prevention. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 13 MSQ‐emotional function." data-id="CD010610-fig-0021" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.13</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 13 MSQ‐emotional function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 14 SF‐36 role physical." data-id="CD010610-fig-0022" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.14</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 14 SF‐36 role physical. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 15 SF‐36 vitality." data-id="CD010610-fig-0023" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.15</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 15 SF‐36 vitality. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 16 SF‐36 physical functioning." data-id="CD010610-fig-0024" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.16</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 16 SF‐36 physical functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 17 SF‐36 bodily pain." data-id="CD010610-fig-0025" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.17</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 17 SF‐36 bodily pain. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 18 SF‐36 general health." data-id="CD010610-fig-0026" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.18</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 18 SF‐36 general health. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 19 SF‐36 social functioning." data-id="CD010610-fig-0027" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.19</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 19 SF‐36 social functioning. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 20 SF‐36 role emotional." data-id="CD010610-fig-0028" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.20</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 20 SF‐36 role emotional. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-002-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-002-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 21 SF‐36 mental health." data-id="CD010610-fig-0029" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.21</div> <div class="figure-caption"> <p>Comparison 2 Topiramate (separate analyses of various doses) versus placebo, Outcome 21 SF‐36 mental health. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-002-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0030" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0031" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 3 MSQ‐role function restrictive." data-id="CD010610-fig-0032" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 3 MSQ‐role function restrictive.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 4 MSQ‐role function prevention." data-id="CD010610-fig-0033" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 4 MSQ‐role function prevention.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 5 MSQ‐emotional function." data-id="CD010610-fig-0034" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 5 MSQ‐emotional function.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 6 SF‐36 role physical." data-id="CD010610-fig-0035" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 6 SF‐36 role physical.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 7 SF‐36 vitality." data-id="CD010610-fig-0036" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 7 SF‐36 vitality.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 8 SF‐36 physical functioning." data-id="CD010610-fig-0037" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 8 SF‐36 physical functioning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 9 SF‐36 bodily pain." data-id="CD010610-fig-0038" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 9 SF‐36 bodily pain.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 10 SF‐36 general health." data-id="CD010610-fig-0039" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 10 SF‐36 general health.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 11 SF‐36 social functioning." data-id="CD010610-fig-0040" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 11 SF‐36 social functioning.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 12 SF‐36 role emotional." data-id="CD010610-fig-0041" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 12 SF‐36 role emotional.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Topiramate direct dose comparisons, Outcome 13 SF‐36 mental health." data-id="CD010610-fig-0042" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Topiramate direct dose comparisons, Outcome 13 SF‐36 mental health.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Topiramate versus amitriptyline, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0043" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Topiramate versus amitriptyline, Outcome 1 Responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Topiramate versus amitriptyline, Outcome 2 MIDAS score." data-id="CD010610-fig-0044" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Topiramate versus amitriptyline, Outcome 2 MIDAS score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-005-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Topiramate versus flunarizine, Outcome 1 Headache frequency (post‐treatment)." data-id="CD010610-fig-0045" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Topiramate versus flunarizine, Outcome 1 Headache frequency (post‐treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Topiramate versus flunarizine, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0046" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Topiramate versus flunarizine, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Topiramate versus propranolol, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone)." data-id="CD010610-fig-0047" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Topiramate versus propranolol, Outcome 1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Topiramate versus propranolol, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0048" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Topiramate versus propranolol, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Topiramate versus sodium valproate, Outcome 1 Headache frequency (post‐treatment)." data-id="CD010610-fig-0049" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Topiramate versus sodium valproate, Outcome 1 Headache frequency (post‐treatment).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Topiramate versus sodium valproate, Outcome 2 MIDAS score." data-id="CD010610-fig-0050" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Topiramate versus sodium valproate, Outcome 2 MIDAS score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Topiramate versus relaxation, Outcome 1 Headache frequency (change from baseline to post‐treatment)." data-id="CD010610-fig-0051" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Topiramate versus relaxation, Outcome 1 Headache frequency (change from baseline to post‐treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-008-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-008-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Topiramate versus relaxation, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency)." data-id="CD010610-fig-0052" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-008-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8 Topiramate versus relaxation, Outcome 2 Responders (patients with ≥ 50% reduction in headache frequency). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-008-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010610-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/urn:x-wiley:14651858:media:CD010610:CD010610-CMP-008-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_t/tCD010610-CMP-008-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Topiramate versus relaxation, Outcome 3 Change from baseline in MSQoL." data-id="CD010610-fig-0053" src="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-008-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8 Topiramate versus relaxation, Outcome 3 Change from baseline in MSQoL.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010610/media/CDSR/CD010610/image_n/nCD010610-CMP-008-03.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD010610-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">NNHs (with 95% CIs), by dose, for placebo‐controlled trials of topiramate and proportion of withdrawals in trials with active intervention or placebo as control</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Type of AE</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>50 mg/day</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>100 mg/day</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>200 mg/day</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any AE</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (7 to 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3 to 12)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (10 to 50)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (8 to 20)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Fatigue</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (17 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (8 to 25)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (17 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12 (9 to 17)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (9 to 50)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Paresthesia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NNH not defined*</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 6)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (2 to 3)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Taste disturbance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (5 to 14)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 (8 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (5 to 11)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25 (14 to 100)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17 (11 to 33)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (8 to 14)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Percentage of patients in active group withdrawing because of AEs</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Afshari 2012: 5%; Ashtari 2008: 3%; Brandes 2004: 17%; Gupta 2007: 2%; Silberstein 2004: 17% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brandes 2004: 26%; de Tommaso 2007: 8%; Diener 2004: 28%; Dodick 2009: 20%; Lipton 2011: 12%; Mei 2004: 29%; Silberstein 2004: 19% </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Brandes 2004: 21%; Diener 2004: 44%; Edwards 2000: 27%; Silberstein 2004: 32%; Silberstein 2006: 15%; Storey 2001: 11%; Varkey 2011: 12% </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>* The 95% CI of the difference in AE rates between treatment and placebo arms (the risk difference, RD) crosses zero. </p> <p>Abbreviations: AE = adverse event; CI = confidence interval; NNH = number needed to harm </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">NNHs (with 95% CIs), by dose, for placebo‐controlled trials of topiramate and proportion of withdrawals in trials with active intervention or placebo as control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/full#CD010610-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0002"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topiramate (combined analyses based on most relevant dose in each study) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.20 [‐1.59, ‐0.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 ORs for responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.18 [2.10, 4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 RRs for responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1246</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.02 [1.57, 2.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Topiramate (combined analyses based on most relevant dose in each study) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topiramate (separate analyses of various doses) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>576</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.95 [‐1.95, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1620</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.15 [‐1.58, ‐0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>804</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.94 [‐1.53, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>575</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [1.60, 3.44]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.49 [2.23, 5.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1025</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.49 [1.61, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Any adverse event <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.07, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>873</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.03, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.20 [0.08, 0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Anorexia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.04, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.05, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Fatigue <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.07, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.04, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Memory problems <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.01, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>758</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.06, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.10, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.01, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>959</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.02, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Paresthesia <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>584</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.21 [‐0.02, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.18, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.39, 0.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Taste disturbance <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.07, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.01, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.09, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Weight loss <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>464</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [0.01, 0.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1270</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.06 [0.03, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [0.07, 0.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 MSQ‐role function restrictive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.83 [2.25, 9.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.08 [6.55, 13.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.36 [6.68, 14.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 MSQ‐role function prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.84 [‐0.24, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.39 [3.37, 9.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.06 [1.87, 8.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 MSQ‐emotional function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.58 [0.61, 8.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.22 [6.31, 14.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.45 [4.38, 12.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 SF‐36 role physical <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.00 [‐3.89, 9.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.80 [‐2.42, 24.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>8.59 [0.65, 16.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 SF‐36 vitality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.08 [‐4.68, 8.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.48 [‐7.77, 16.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.36 [‐4.52, 7.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 SF‐36 physical functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [‐3.28, 4.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.78 [‐3.29, 8.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐5.27, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 SF‐36 bodily pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.35 [0.04, 8.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.35 [‐1.29, 14.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.12 [‐1.25, 11.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 SF‐36 general health <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [‐2.18, 5.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.18 [‐1.21, 9.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [‐1.00, 6.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 SF‐36 social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.00 [‐1.92, 5.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.13 [‐3.73, 9.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.94 [‐2.07, 5.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 SF‐36 role emotional <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.30 [‐4.56, 9.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.64 [‐3.39, 12.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.75 [‐4.99, 10.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 SF‐36 mental health <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Topiramate titrated to 50 mg/day or maximum tolerated dose &lt; 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.19 [‐4.59, 6.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.2 Topiramate titrated to 100 mg/day or maximum tolerated dose &lt; 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.58 [‐5.65, 10.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.3 Topiramate titrated to 200 mg/day or maximum tolerated dose &lt; 200 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>458</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.57 [‐4.21, 7.35]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Topiramate (separate analyses of various doses) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topiramate direct dose comparisons</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.71 [‐1.32, ‐0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.96 [‐1.53, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.55, 0.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [1.25, 2.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>462</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.66 [1.15, 2.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.69, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 MSQ‐role function restrictive <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.22 [0.65, 7.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.55 [0.82, 8.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [‐3.37, 3.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 MSQ‐role function prevention <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.54 [0.48, 6.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.28 [‐2.13, 6.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.18 [‐6.67, 4.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 MSQ‐emotional function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.62 [1.67, 9.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.90 [‐0.21, 8.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.73 [‐5.80, 2.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 SF‐36 role physical <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.70 [‐8.27, 23.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.51 [‐5.17, 16.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐9.31, 4.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 SF‐36 vitality <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.44 [‐3.05, 7.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.63 [‐4.64, 3.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.01 [‐9.38, 3.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 SF‐36 physical functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.35 [‐1.02, 5.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.44 [‐4.92, 2.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.75 [‐7.18, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 SF‐36 bodily pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.13 [‐1.83, 6.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [‐3.27, 4.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.16 [‐5.23, 2.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 SF‐36 general health <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.72 [‐0.76, 6.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [‐4.36, 6.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐8.85, 5.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 SF‐36 social functioning <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.13 [‐5.53, 7.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐4.07, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.05 [‐5.56, 3.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 SF‐36 role emotional <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.33 [‐3.79, 8.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [‐5.69, 6.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.65 [‐7.92, 4.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 SF‐36 mental health <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Topiramate 100 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>479</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.31 [‐1.87, 4.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Topiramate 200 mg versus 50 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [‐2.87, 3.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.3 Topiramate 200 mg versus 100 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>474</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐4.10, 2.36]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Topiramate direct dose comparisons</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topiramate versus amitriptyline</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MIDAS score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Topiramate versus amitriptyline</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topiramate versus flunarizine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (post‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Topiramate versus flunarizine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topiramate versus propranolol</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (change from baseline to post‐treatment, or post‐treatment alone) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.61, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Topiramate 50 mg versus propranolol 80 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.37 [‐1.15, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topiramate 100 mg versus propranolol 160 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>282</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.60, 0.60]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Topiramate versus propranolol</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Topiramate versus sodium valproate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (post‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>120</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.90 [‐1.58, ‐0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 MIDAS score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Topiramate versus sodium valproate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD010610-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topiramate versus relaxation</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Headache frequency (change from baseline to post‐treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Responders (patients with ≥ 50% reduction in headache frequency) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Change from baseline in MSQoL <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Topiramate versus relaxation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010610/references#CD010610-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010610&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010610-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010610-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010610-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD010610-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD010610-note-0001">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD010610-note-0002">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010610\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010610"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010610\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010610\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010610"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010610\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010610"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010610\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010610\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010610"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PSzzz2OT&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010610&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010610';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010610/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010610/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010610%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718877228"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010610/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718877232"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010610/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ddb100b12935f',t:'MTc0MDcxODg3Ny4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 